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Abstract 
Eukaryotic translation elongation factor 1 delta 
pseudogene 3, alias EEF1DP3, is a pseudogene. This 
review collects the data about its DNA/RNA and on 
the diseases where it is involved. 
Keywords 
EEF1DP3; eukaryotic translation elongation factor 1 
delta pseudogene 3; ankylosing spondylitis; cancer; 
oncogenesis 
Identity 
Other names 
EEF1DP3-201, MGC149669, MGC149670, 
Putative Elongation Factor 1-Delta-Like Protein, 
Putative EF-1-Delta-Like Pseudogene 3 Protein 
HGNC (Hugo) : EEF1DP3 
Location : 13q13.1 
DNA/RNA 
Description 
EEF1DP3, alias eukaryotic translation elongation 
factor 1 delta pseudogene 3, is a pseudogene and it 
is located on chromosome 13 that is known to bring 
some putative oncogenes involved in cancer 
including the breast cancer type 2 (BRCA2) and the 
retinoblastoma (RB1) genes (Dunham et al., 2004). 
The related functional gene is the "eukaryotic 
translation elongation factor 1 delta" (EEF1D) that is 
located on chromosome 8 (8q24.3).  
EEF1DP3 starts at 31,846,783 nt and ends at 
31,959,584 from pter. It has a length of 112,802 bp 
and the current reference sequence is NC_000013.11 
(Dunham et al., 2004). 
Figure. 1. EEF1DP3 gene. The figure shows the locus on chromosome 13 of the EEF1DP3 gene (reworked from 
https://www.ncbi.nlm.nih.gov/gene; http://grch37.ensembl.org; www.genecards.org) 
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It is proximal to the 'relaxin family peptide receptor 
2' (RXFP2) gene and FRY microtubule binding 
protein (FRY) gene. Curiously, closer to the 
genomic sequence of EEF1DP3 there is a promoter 
element that is located at -0.1 kb. This promoter 
element exercises its influence also on genes closer 
to EEF1DP3, i.e. FRY and RXFP2.  
EEF1DP3 is classified as a transcribed unprocessed 
pseudogene. In the genomic sequence there are 4 
non-coding exons. 
Transcription 
EEF1DP3 pseudogene is transcribed and produces a 
long non-coding RNA (lncRNA) of 575 nt (Kimura 
et al., 2006) with a reference sequence 
NR_027062.1. It is still unknown if it is subjected to 
post-transcriptional modifications, such as 5'-
capping, 3'-polyadenylation or splicing. However, 
other alternative transcripts are reported: EEF1DP3-
001, a processed transcript of 1309 nt, EEF1DP3-
002, a retained intron of 3283 nt and EEF1DP3-003, 
a transcribed unprocessed pseudogene of 782 nt 
(http://phase3browser.1000genomes.org). It seems 
that EEF1DP3 is overexpressed in heart, in particular 
in the left ventricle (https://www.genecards.org) and 
also expressed in normal trachea, liver, testis, 
kidney, bladder and brain (http://source-
search.princeton.edu/). On the contrary, a low 
expression is detected in adrenal gland, colon and 
pituitary gland 
(https://amp.pharm.mssm.edu/Harmonizome/gene/
EEF1DP3). It is known that lncRNAs, as 
pseudogenes as well as the others ncRNAs, may 
modulate the gene expression both at the 
transcriptional level, interacting with the promotor 
of parental gene o other genes, and post-
transcriptional level, acting as microRNA decoys 
and so they may play key roles in cellular biological 
processes (Chan and Tay, 2018; Hu et al., 2018; 
Kovalenko and Patrushev, 2018). Nowadays, is still 
unknown the exact role of EEF1DP3 in healthy 
tissues. 
Protein 
EEF1DP3 seems to be able to produce a lncRNA but 
there are no proofs about the existence of a codified 
protein. However, is reported in some databases 
(UniProtKB; InterPro) a protein product also for this 
pseudogene, called "putative elongation factor 1-
delta-like protein", alias EF1DL (accession number: 
Q658K8).  
Until recently, it was believed that pseudogenes were 
not able to encode a protein, but recent 
transcriptomic and proteomic analyses seem to 
demonstrate not only the presence of pseudogene-
derived transcripts but also of pseudogene-derived 
proteins (Chan and Tay, 2018; Kim et al., 2014; 
Djebali et al., 2012). Although it is still unclear if the 
protein EF1DL can be displayed or not, its presence 
should be not excluded. This protein should be 133 
amino acids long and should have a molecular 
weight of 14,137 kDa and a theoretical pI of 5.94. 
Curiously, EF1DL shows 90% of identity with an 
uncharacterized protein (H2NJJ9_PONAB) of 
similar mass and length present in Sumatran 
orangutan (Pongo pygmaeus abelii) and linked to its 
chromosome 13. Bioinformatic analysis of the 
comparison between EF1DL protein and eEF1D 
isoforms (pblast) revealed that there is an 85% of 
identity between EF1DL (1-90 aa) and a fragment of 
the long isoform of eEF1D (367-458 aa) and that is 
included a little portion of the second leucine-zipper 
domain of eEF1D. A similar result is obtained 
between EF1DL (1-90 aa) and the short form of 
eEF1D (1-92 aa) with the inclusion of a little portion 
of the unique leucine-zipper domain of the short 
form of eEF1D.  
EF1DL could take a significant aspect in relation to 
cellular alterations observed in cancer that frequently 
juxtapose genomic elements next to strong promotor 
elements to produce unusual proteins that contribute 
to its malignant behavior and its aggressiveness. In 
fact, it is reported the involvement of EEF1DP3 in 
some genomic rearrangements and although there 
are no sufficient data yet to clarify these phenomena 
it cannot be excluded that EEF1DP3 can bring to a 
protein product after significative genomic 
alterations. 
Mutations 
Have been discovered a large number of mutations 
and alterations in the genomic sequence for 
EEF1DP3. The genomic alterations observed 
include copy number variations, translocations and 
interchromosomal translocations with the formation 
of novel fusion genes. However, there are no 
sufficient experimental data yet to understand the 
repercussions on cellular behavior of these fusion 
genes. 
Implicated in 
Top note 
It is known that the aberrant expression of lncRNAs, 
as pseudogenes as well as the others ncRNAs, could 
have an important role in cancer development and 
progression (Chan and Tay, 2018; An et al., 2017). 
EEF1DP3 was found highly expressed in some 
healthy tissue types and also in many cancer types 
and this suggests that it could act as a positive 
regulator of gene expression, with high probability 
for its parental gene EEF1D and maybe also for other 
genes. In fact, it is known that the pseudogenes may 
act as positive regulators or negative regulators of 
gene expression (Hu et al., 2008). However, its role 
is still to be determined. 
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Name 5' end 3' end Loc1 Loc2 Description Type Disease Organ Code Ref.< 
APC/EEF1DP3 APC EEF1DP3 
 5q22.
2 
13q13.
1 
t(5;13)(q22;q13)
  
Translocatio
n 
(?) - - - 
EEF1DP3/BLVR
B 
EEF1DP3 BLVRB 
13q13.
1 
19q13.
2 
t(13;19)(q13;q1
3)  
Translocatio
n 
Sarcoma 
Soft 
tissue 
SAR
C 
- 
EEF1DP3/CLDN1
0 
EEF1DP3 CLDN10 
13q13.
1 
13q32.
1 
t(13;13)(q13;q3
2)  
Fusion gene 
Adenocarcino
ma 
Breast 
BRC
A 
Alaei-
Mahabad
i et al., 
2016 
 EEF1DP3/FRY 
 EEF1DP
3  
FRY 
13q13.
1 
13q13.
1 
Readthrough 
transcription 
Fusion gene 
Adenocarcino
ma 
Breast 
BRC
A 
Kim et 
al., 2015 
Burkitt 
lymphoma 
Blood BL - 
Adenocarcino
ma 
Lung 
LUA
D 
- 
Malignant 
melanoma 
Skin 
SKC
M 
- 
Nonneoplastic 
epithelial 
disorder/lesion 
 Adrenal 
gland 
- 
Babicean
u et al., 
2016 
Nonneoplastic 
epithelial 
disorder/lesion 
Bladder - 
- 
Bone 
marrow 
- 
- 
Embryoni
c stem 
cells (cell 
line) 
ESC 
Nonneoplastic 
mesenchymal 
disorder/lesion 
Heart - 
Nonneoplastic 
epithelial 
disorder/lesion 
Skin - 
Nonneoplastic 
epithelial 
disorder/lesion 
 Stomach - 
Nonneoplastic 
epithelial 
disorder/lesion 
 Testis - 
Nonneoplastic 
epithelial 
disorder/lesion 
 Thyroid - 
EEF1DP3/N4BP2
L1 
EEF1DP3 N4BP2L1 
13q13.
1 
13q13.
1 
t(13;13)(q13;q1
3)  
Fusion gene 
Adenocarcino
ma 
Breast 
BRC
A 
- 
EEF1DP3/TEX26 EEF1DP3 TEX26 
13q13.
1 
13q12.
3 
t(13;13)(q13;q1
2)  
Fusion gene 
Adenocarcino
ma 
Breast 
BRC
A 
- 
EEF1DP3/TLK1 EEF1DP3 TLK1 
13q13.
1 
 2q31.
1 
t(2;13)(q31;q13)
  
Translocatio
n 
Burkitt 
lymphoma 
Blood BL - 
NCL/EEF1DP3 NCL 
 EEF1DP
3  
13q13.
1 
13q13.
1 
t(13;13)(q13;q1
3)  
Fusion gene (?) - - - 
Table.1 EEF1DP3 rearrangements: translocations and fusion genes (reworked from https://cgap.nci.nih.gov/Chromosomes; 
http://atlasgeneticsoncology.org//Bands/13q13.html#REFERENCES; https://fusionhub.persistent.co.in/home.html; 
https://ccsm.uth.edu/FusionGDB/index.html)[(?)] unknown;  [-] no reference 
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Figure.2 Circos plot for fusion events involving EEF1DP3.  
The picture summarizes all fusion events concerning 
EEF1DP3 and its fusion partners (from 
https://fusionhub.persistent.co.in/search_genewise.html). 
EEF1DP3/FRY read-through fusion 
EEF1DP3/FRY is a recurrent read-through fusion 
transcript that is found in some types of 
nonneoplastic disorders and in some types of tumors 
such as malignant melanoma, Burkitt lymphoma, 
lung cancer and breast cancer (Babiceanu et al., 
2016; Kim et al., 2015; Kim et al., 2011; 
https://fusionhub.persistent.co.in/ home.html; 
https://ccsm.uth.edu/FusionGDB/ index.html).  
The off-frame fusion of these two adjacent genes 
brings to the formation of a novel transcript formed 
by the 1 and 2 exons of EEF1DP3 joined with the 
exons from 2 to 61 of FRY.  
This results in an insertion of a stop codon in the 
nucleotidic sequence with an early truncation with 
loss-of-function of the FRY gene (Kim et al., 2015). 
Adrenal carcinoma 
EEF1DP3 is reported to be highly expressed 
inadrenocortical carcinoma (ACC) and 
pheochromocytoma and other paraganglioma 
(PCPG) samples (Cancer Genome Atlas Research 
Network et al., 2013; https://amp.pharm.mssm.edu/ 
Harmonizome/gene/EEF1DP3). 
Ankylosing Spondylitis 
EEF1DP3 seems to be involved in some variants 
associated with ankylosing spondylitis (AS), a 
chronic and complex autoimmune disorder. In 
particular, it was found a loss in EEF1DP3 due to its 
deletion and this has been associated with an 
increased risk and predisposition for AS (Shahba et 
al., 2018; Yim et al., 2015; Jung et al., 2014). 
Brain and central nervous system 
(CNS) cancers 
EEF1DP3 is reported to be highly expressed in brain 
lower grade glioma (LGG) (Cancer Genome Atlas 
Research Network et al., 2013; 
https://amp.pharm.mssm.edu/Harmonizome/gene/E
EF1DP3). 
Breast Cancer 
Some fusion genes caused by intrachromosomal 
translocations were reported for EEFDP3 in breast 
cancer (Alaei-Mahabadi et al., 2016; Babiceanu et 
al., 2016; Kim et al., 2015; 
https://fusionhub.persistent.co.in/home.html). 
Hybrid/Mutated gene 
All fusion genes reported until now between 
EEF1DP3 and other partner genes are due to 
intrachromosomal translocations except the more 
known fusion gene EEF1DP3/FRY that is the result 
of a fusion between EEF1DP3 at 5'-end and "FRY 
microtubule binding protein" ( FRY) gene at 3'-end 
(Kim et al., 2015) and it is due to a readthrough 
transcription. This fusion gene was found also in 
nonneoplastic epithelial disorders or in healthy 
tissues, so its presence in the cell seems to be not 
only linked with neoplastic transformation. Its 
biological significance needs to be clarified as well 
as its role in the cells and in cancer cells.  
Other fusion genes are reported such as 
EEF1DP3/CLDN10 that is originated by fusion of 
EEF1DP3 at 5'-end with "claudin 10" ( CLDN10) 
gene at 3'-end (Alaei-Mahabadi et al., 2016), 
EEF1DP3/N4BP2L1 that is originated by fusion of 
EEF1DP3 at 5'-end with "NEDD4 binding protein 2 
like 1" ( N4BP2L1) gene at 3'-end and finally 
EEF1DP3/TEX26 that is originated by fusion of 
EEF1DP3 at 5'-end with "testis expressed 26" ( 
TEX26) gene at 3'-end. The significance of these 
genomic alterations is still poorly understood. 
Colorectal cancer 
EEF1DP3 is reported to be highly expressed in 
rectum adenocarcinoma (READ) samples (Cancer 
Genome Atlas Research Network et al., 2013; 
https://amp.pharm.mssm.edu/Harmonizome/gene/E
EF1DP3). 
Gynaecological cancers 
EEF1DP3 is reported to be highly expressed in 
cervical squamous cell carcinoma and endocervical 
adenocarcinoma (CESC) samples and also in uterine 
carcinosarcoma (UCS) (Cancer Genome Atlas 
Research Network et al., 2013; 
https://amp.pharm.mssm.edu/Harmonizome/gene/E
EF1DP3). 
Head and neck squamous cell 
carcinoma (HNSC) 
EEF1DP3 is reported to be highly expressed in head 
and neck squamous cell carcinoma (HNSC) samples 
(Cancer Genome Atlas Research Network et al., 
2013; https://amp.pharm.mssm.edu/ 
Harmonizome/gene/EEF1DP3). 
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Liver cancer 
EEF1DP3 is reported to be highly expressed in liver 
hepatocellular carcinoma samples (LIHC) (Cancer 
Genome Atlas Research Network et al., 2013; 
https://amp.pharm.mssm.edu/Harmonizome/gene/E
EF1DP3). 
Lung cancer 
EEF1DP3 is reported to be highly expressed in lung 
adenocarcinoma (LUAD), lung squamous cell 
carcinoma (LUSC) and mesothelioma (MESO) 
samples (Cancer Genome Atlas Research Network et 
al., 2013; https://amp.pharm.mssm.edu/ 
Harmonizome/gene/EEF1DP3). 
Lymphoma, leukaemia and other 
blood cancers 
EEF1DP3 is reported to be highly expressed in acute 
myeloid leukemia (AML) and lymphoid neoplasm 
diffuse large B-cell lymphoma (DLBC) (Cancer 
Genome Atlas Research Network et al., 2013; 
https://amp.pharm.mssm.edu/Harmonizome/gene/E
EF1DP3) and are reported the fusion gene EEF1DP3 
/FRY and the translocation t(2;13)(q31;q13) 
EEF1DP3/TLK1 in Burkitt lymphoma 
(https://fusionhub.persistent.co.in/home.html). 
Hybrid/Mutated gene 
The t(2;13)(q31;q13) EEF1DP3/TLK1 and 
EEF1DP3/FRY fusion gene were found in Burkitt 
lymphoma. The first rearrangement is originated by 
the fusion of EEF1D gene at 5'-end with "tousled like 
kinase 1" (TLK1) gene at 3' end while the 
EEF1DP3/FRY fusion gene is originated by the 
fusion of EEF1D gene at 5'-end with "FRY 
microtubule binding protein" (FRY) gene at 3' end 
and it is probably due to readthrough transcription. 
In fact, EEF1D and FRY are two neighboring genes 
on the same chromosome. There are no data about 
the chimeric transcripts or proteins and the role of 
these genomic alterations are still unknown. 
Melanoma 
EEF1DP3 is reported to be highly expressed in skin 
cutaneous melanoma (SKCM) samples (Cancer 
Genome Atlas Research Network et al., 2013; 
https://amp.pharm.mssm.edu/Harmonizome/gene/E
EF1DP3). 
Neurodegenerative disorders 
EEF1DP3 seems to be related to various 
neurodegenerative disorders as synucleinopathy and 
Parkinson's disease (https://amp.pharm.mssm.edu/ 
Harmonizome/gene/EEF1DP3). 
Pancreatic cancer 
EEF1DP3 is reported to be highly expressed in 
pancreatic adenocarcinoma (PAAD) samples 
(Cancer Genome Atlas Research Network et al., 
2013; https://amp.pharm.mssm.edu/Harmonizome/ 
gene/EEF1DP3). 
Prostate Cancer 
Erho and colleagues found that EEF1DP3 is 
differentially expressed between normal prostate 
tissues and primary and metastatic prostate cancer 
samples (Erho et al., 2012) and other authors confirm 
this overexpression in prostate adenocarcinoma 
(PRAD) (Cancer Genome Atlas Research Network 
et al., 2013; 
https://amp.pharm.mssm.edu/Harmonizome/gene/E
EF1DP3). 
Sarcoma 
EEF1DP3 is revealed to be highly expressed in 
sarcoma (SARC) samples (Cancer Genome Atlas 
Research Network et al., 2013; 
https://amp.pharm.mssm.edu/Harmonizome/gene/E
EF1DP3) and was reported the translocation 
t(13;19)(q13;q13) EEF1DP3/BLVRB 
(https://fusionhub.persistent.co.in/home.html). 
Hybrid/Mutated gene 
The t(13;19)(q13;q13) EEF1DP3/BLVRB was 
found in sarcoma. This rearrangement is originated 
by the fusion of EEF1D gene at 5'-end with 
'biliverdin reductase B' (BLVRB) gene at 3' end. 
There are no data about the respective chimeric 
transcript or protein and the role of this genomic 
alteration is unknown. 
Urinary tract cancers 
EEF1DP3 is reported to be highly expressed in 
bladder urothelial carcinoma (BLCA) samples and 
also in chromophobe renal cell carcinoma (KICH), 
clear cell renal cell carcinoma (KIRC) and papillary 
renal cell carcinoma (KIRP) (Cancer Genome Atlas 
Research Network et al., 2013; 
https://amp.pharm.mssm.edu/Harmonizome/gene/E
EF1DP3). 
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